Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8858956 | 0.79 | USP2 (0.33) | BCL2L1USP2 | |
| SCHEMBL30875818 | 0.74 | CD81 (0.38) | BCL2L1USP2 | |
| SCHEMBL22600 | 0.74 | CD81 (0.38) | BCL2L1USP2 | |
| SCHEMBL112617 | 0.74 | CD81 (0.38) | BCL2L1USP2 | |
| SCHEMBL5481525 | 0.73 | CA1 (0.30) | — | |
| Acetic Acid SCHEMBL5177748 | 0.72 | CD81 (0.37) | BCL2L1USP2 | |
| Bromide SCHEMBL1061720 | 0.72 | CD81 (0.37) | BCL2L1USP2 | |
| SCHEMBL8972208 | 0.72 | EP300 (0.50) | USP2 | |
| Hydrochloric Acid SCHEMBL966904 | 0.72 | CD81 (0.37) | BCL2L1USP2 | |
| Hydrochloric Acid SCHEMBL1396403 | 0.72 | CD81 (0.37) | BCL2L1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2556825-A1 | Multicomponent pharmaceutical dosage form | Capsugel Belgium NV (BE) | 2013-02-13 | — | — | EP | disclosed |
| EP-1528916-B1 | MULTICOMPONENT PHARMACEUTICAL DOSAGE FORM | CAPSUGEL BELGIUM NV (BE) | 2012-12-26 | — | — | EP | disclosed |
| US-20060057201-A1 | Multicomponent pharmaceutical dosage form | CAPSUGEL BELGIUM BVBA (BE) | 2006-03-16 | — | — | US | disclosed |
| EP-1528916-A1 | MULTICOMPONENT PHARMACEUTICAL DOSAGE FORM | GLAXO GROUP LIMITED (GB) | 2005-05-11 | — | — | EP | disclosed |
| WO-2004010978-A1 | MULTICOMPONENT PHARMACEUTICAL DOSAGE FORM | GLAXO GROUP LIMITED (GB) | 2004-02-05 | — | — | WO | disclosed |